MedPath

Examination for the effect of combination therapy with alendronate and eldecalcitol in primary osteoporotic patients :A randomized active comparator study -Switch from alfacalcidol to eldecalcitol

Not Applicable
Conditions
Osteoporosis
Registration Number
JPRN-UMIN000006964
Lead Sponsor
Tokyo Women's Medical University Medical Center East
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
120
Inclusion Criteria

Not provided

Exclusion Criteria

(1) Patients who are diagnosed as contraindication of alendronate treatments (2) Patients who are diagnosed as contraindication of eldecalcitol treatments (3) Patients who are treated with glucocorticoid (4) Patients who have serum calcium levels of above 10.5mg/dL (5) Patients who have taken osteoporosis treatments other than alendronate and alfacalcidol (6) Patients who are inappropriate for this study by physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath